Halyard Health, Inc. (HYH) Stock Rating Upgraded by TheStreet
Halyard Health, Inc. (NYSE:HYH) was upgraded by investment analysts at TheStreet from a “c” rating to a “b” rating in a research report issued to clients and investors on Thursday.
Several other research firms have also weighed in on HYH. Stifel Nicolaus lifted their price objective on Halyard Health from $38.00 to $45.00 and gave the stock a “buy” rating in a research report on Tuesday, February 28th. Stephens lowered Halyard Health from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, February 28th. Finally, Zacks Investment Research lowered Halyard Health from a “hold” rating to a “sell” rating in a research report on Thursday, March 2nd. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $40.50.
Shares of Halyard Health (NYSE HYH) traded up 2.19% during midday trading on Thursday, hitting $39.73. The company’s stock had a trading volume of 852,649 shares. Halyard Health has a 1-year low of $30.88 and a 1-year high of $41.84. The company has a market cap of $1.86 billion, a P/E ratio of 48.39 and a beta of 1.79. The company has a 50-day moving average price of $37.16 and a 200 day moving average price of $38.29.
Halyard Health (NYSE:HYH) last posted its quarterly earnings data on Tuesday, May 2nd. The medical instruments supplier reported $0.48 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.43 by $0.05. Halyard Health had a return on equity of 8.16% and a net margin of 2.40%. The firm had revenue of $395.60 million during the quarter, compared to analyst estimates of $391.56 million. During the same period last year, the company posted $0.53 EPS. The business’s quarterly revenue was up 2.8% on a year-over-year basis. On average, equities research analysts predict that Halyard Health will post $1.85 EPS for the current year.
A number of hedge funds have recently modified their holdings of the stock. BlackRock Inc. raised its stake in shares of Halyard Health by 6,362.1% in the first quarter. BlackRock Inc. now owns 5,939,352 shares of the medical instruments supplier’s stock worth $226,229,000 after buying an additional 5,847,442 shares during the last quarter. Norges Bank purchased a new stake in shares of Halyard Health during the fourth quarter worth approximately $38,025,000. Cambiar Investors LLC purchased a new stake in shares of Halyard Health during the fourth quarter worth approximately $25,026,000. Copper Rock Capital Partners LLC purchased a new stake in shares of Halyard Health during the first quarter worth approximately $26,763,000. Finally, JPMorgan Chase & Co. raised its stake in shares of Halyard Health by 704.7% in the third quarter. JPMorgan Chase & Co. now owns 608,265 shares of the medical instruments supplier’s stock worth $21,082,000 after buying an additional 532,677 shares during the last quarter. 91.87% of the stock is owned by institutional investors and hedge funds.
About Halyard Health
Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.
Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.